Evaluating Neuroprotection in Aneurysm Coiling Therapy "ENACT"

Completed

Phase 2 Results

Summary of Purpose

This is a randomized, double-blind, placebo-controlled, single-dose, design investigating the safety, tolerability and efficacy of NA-1, a peptide designed to reduce ischemic brain damage. Up to 200 male and female patients undergoing endovascular repair of brain aneurysm will be dosed with 2.60 mg/kg of NA-1 or placebo as a 10 minute intravenous infusion after completion of the endovascular procedure on Day 1...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 9 August 2013.

1 Aug 2008 1 Aug 2008 1 Apr 2011 1 May 2011 1 Aug 2013 8 May 2013
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • Sponsor Contact Information: Roberta M Anderson, Ph.D. (Primary) Phone: (613) 833-1020 Email: roberta_nonoinc@rogers.com Secondary Contact: Julie Bishop,M.A. Phone: (613) 728-0576 Email: Jbishop.nono@sympatico.ca

    roberta_nonoinc@rogers.com